Actively Recruiting

Phase 1
Age: 18Years +
All Genders
NCT05723107

EUS RFA for Treatment of Pancreatic Ductal Adenocarcinoma (PDAC)

Led by NYU Langone Health · Updated on 2025-11-28

15

Participants Needed

1

Research Sites

256 weeks

Total Duration

On this page

Sponsors

N

NYU Langone Health

Lead Sponsor

T

Taewoong Medical

Collaborating Sponsor

AI-Summary

What this Trial Is About

This is a single arm study in the treatment of pancreatic ductal adenocarcinoma (PDAC). The investigators propose to test the tolerability of chemotherapy plus endoscopic ultrasound-guided radiofrequency ablation (EUS-RFA) using the RF Electrode in patients receiving palliative second or third line therapy for unresectable non-metastatic pancreatic cancer.

CONDITIONS

Official Title

EUS RFA for Treatment of Pancreatic Ductal Adenocarcinoma (PDAC)

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Diagnosed and histologically confirmed pancreatic ductal adenocarcinoma (PDAC) by biopsy
  • Axial CT scan or MRI showing PDAC with at least 1 cm in greatest diameter
  • ECOG performance status of 0 to 2
  • Locally advanced PDAC with no response or progression after first line chemotherapy
  • Tumor deemed unresectable after multidisciplinary review
  • No evidence of distant metastasis
  • Tumor lesions between 1 and 4 cm in size
Not Eligible

You will not qualify if you...

  • Evidence of distant metastasis
  • Tumor mass not accessible by endoscopy
  • Pregnancy
  • Unable to provide informed consent
  • Tumor lesions smaller than 1 cm or larger than 4 cm in greatest diameter

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Tisch Hospital

New York, New York, United States, 10016

Actively Recruiting

Loading map...

Research Team

T

Tamas A. Gonda, MD

CONTACT

E

Emil Agarunov

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

TREATMENT

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

EUS RFA for Treatment of Pancreatic Ductal Adenocarcinoma (PDAC) | DecenTrialz